These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 9458680)
1. Passive immunization for the treatment of HIV infection. Jacobson JM Mt Sinai J Med; 1998 Jan; 65(1):22-6. PubMed ID: 9458680 [TBL] [Abstract][Full Text] [Related]
2. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Trkola A; Kuster H; Rusert P; Joos B; Fischer M; Leemann C; Manrique A; Huber M; Rehr M; Oxenius A; Weber R; Stiegler G; Vcelar B; Katinger H; Aceto L; Günthard HF Nat Med; 2005 Jun; 11(6):615-22. PubMed ID: 15880120 [TBL] [Abstract][Full Text] [Related]
3. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group. DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166 [TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies take a swipe at HIV in vivo. Montefiori DC Nat Med; 2005 Jun; 11(6):593-4. PubMed ID: 15937465 [No Abstract] [Full Text] [Related]
5. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172 [TBL] [Abstract][Full Text] [Related]
6. Passive immunization for the treatment and prevention of HIV infection. Karwowska S; Zolla-Pazner S Biotechnol Ther; 1991; 2(1-2):31-48. PubMed ID: 1845123 [TBL] [Abstract][Full Text] [Related]
7. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). Stiehm ER; Fletcher CV; Mofenson LM; Palumbo PE; Kang M; Fenton T; Sapan CV; Meyer WA; Shearer WT; Hawkins E; Fowler MG; Bouquin P; Purdue L; Sloand EM; Nemo GJ; Wara D; Bryson YJ; Starr SE; Petru A; Burchett S J Infect Dis; 2000 Feb; 181(2):548-54. PubMed ID: 10669338 [TBL] [Abstract][Full Text] [Related]
8. Honing the immune attack on HIV. Gilden D GMHC Treat Issues; 1996 Dec; 10(12):8-11. PubMed ID: 11364019 [TBL] [Abstract][Full Text] [Related]
9. Immunology. Close to the edge: neutralizing the HIV-1 envelope. Nabel GJ Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295 [No Abstract] [Full Text] [Related]
10. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV). Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851 [TBL] [Abstract][Full Text] [Related]
11. [One antibody preparation is not another: the role of passive immunotherapy in the treatment of HIV infection]. Leverstein-van Hall MA; Goudsmit J Ned Tijdschr Geneeskd; 1995 Feb; 139(7):316-20. PubMed ID: 7877699 [No Abstract] [Full Text] [Related]
12. Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy. Powderly WG Clin Infect Dis; 2000 Aug; 31(2):597-601. PubMed ID: 10987727 [TBL] [Abstract][Full Text] [Related]
13. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948 [TBL] [Abstract][Full Text] [Related]
14. Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease. Veljkovic V; Metlas R Int Rev Immunol; 2004; 23(5-6):437-45. PubMed ID: 15370275 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. Stiegler G; Katinger H J Antimicrob Chemother; 2003 Apr; 51(4):757-9. PubMed ID: 12654737 [No Abstract] [Full Text] [Related]
16. Active and passive immunization against HIV type 1 infection in chimpanzees. Murthy KK; Cobb EK; Rouse SR; McClure HM; Payne JS; Salas MT; Michalek GR AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S271-6. PubMed ID: 9814955 [TBL] [Abstract][Full Text] [Related]
17. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
18. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV. Ali Tabei SM; Li Y; Weigert M; Dinner AR Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591 [TBL] [Abstract][Full Text] [Related]
19. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Ferrantelli F; Buckley KA; Rasmussen RA; Chalmers A; Wang T; Li PL; Williams AL; Hofmann-Lehmann R; Montefiori DC; Cavacini LA; Katinger H; Stiegler G; Anderson DC; McClure HM; Ruprecht RM Virology; 2007 Feb; 358(1):69-78. PubMed ID: 16996554 [TBL] [Abstract][Full Text] [Related]
20. Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression. Nnoruka EN; Chukwuka JC; Anisuiba B Int J Dermatol; 2007 Oct; 46 Suppl 2():14-8. PubMed ID: 17958624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]